Lilly posts $23 billion quarter as Mounjaro hits $9.9 billion
Management lifted full-year revenue guidance to $85 billion to $87 billion, from a prior range of $82 billion to $85 billion.
TR
By Tom Reyes · Markets Editor
Aug 5 03:00 ETSource: 24/7 Wall St.
The wire
- 01Eli Lilly reported second-quarter revenue up 48% year over year to $23 billion, net income of $7.1 billion and adjusted EPS of $8.38, all above consensus.
- 02Mounjaro at $9.9 billion in quarterly sales is now the world's best-selling drug, against Novo Nordisk's $4.8 billion Ozempic and roughly $500 million Wegovy quarter.
- 03The outlet frames Lilly's next decade around a joint AI lab with Nvidia worth up to $1 billion over five years; that investment thesis is commentary, not a company forecast.
From the source
Read at 247wallst.comGLP-1’s Drove Eli Lilly’s Record-Breaking Q2, but AI Will Be Its Future
Eli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may not be what defines the company a decade from now. A billion-dollar bet on artificial intelligence could change everything.